219 related articles for article (PubMed ID: 36490253)
1. Obeticholic acid treatment ameliorates the cardiac dysfunction in NASH mice.
Liu SY; Huang CC; Yang YY; Huang SF; Lee TY; Li TH; Hou MC; Lin HC
PLoS One; 2022; 17(12):e0276717. PubMed ID: 36490253
[TBL] [Abstract][Full Text] [Related]
2. A new mechanism of obeticholic acid on NASH treatment by inhibiting NLRP3 inflammasome activation in macrophage.
Huang S; Wu Y; Zhao Z; Wu B; Sun K; Wang H; Qin L; Bai F; Leng Y; Tang W
Metabolism; 2021 Jul; 120():154797. PubMed ID: 33984334
[TBL] [Abstract][Full Text] [Related]
3. Increased hepatoprotective effects of the novel farnesoid X receptor agonist INT-787 versus obeticholic acid in a mouse model of nonalcoholic steatohepatitis.
Adorini L; Rigbolt K; Feigh M; Roth J; Erickson M
PLoS One; 2024; 19(4):e0300809. PubMed ID: 38662778
[TBL] [Abstract][Full Text] [Related]
4. Superior reductions in hepatic steatosis and fibrosis with co-administration of a glucagon-like peptide-1 receptor agonist and obeticholic acid in mice.
Jouihan H; Will S; Guionaud S; Boland ML; Oldham S; Ravn P; Celeste A; Trevaskis JL
Mol Metab; 2017 Nov; 6(11):1360-1370. PubMed ID: 29107284
[TBL] [Abstract][Full Text] [Related]
5. Ursodeoxycholic acid is a GPBAR1 agonist and resets liver/intestinal FXR signaling in a model of diet-induced dysbiosis and NASH.
Carino A; Biagioli M; Marchianò S; Fiorucci C; Zampella A; Monti MC; Scarpelli P; Ricci P; Distrutti E; Fiorucci S
Biochim Biophys Acta Mol Cell Biol Lipids; 2019 Oct; 1864(10):1422-1437. PubMed ID: 31325638
[TBL] [Abstract][Full Text] [Related]
6. Obeticholic acid-a new therapy in PBC and NASH.
Chapman RW; Lynch KD
Br Med Bull; 2020 May; 133(1):95-104. PubMed ID: 32282030
[TBL] [Abstract][Full Text] [Related]
7. FXR agonists for MASH therapy: Lessons and perspectives from obeticholic acid.
Wang K; Zhang Y; Wang G; Hao H; Wang H
Med Res Rev; 2024 Mar; 44(2):568-586. PubMed ID: 37899676
[TBL] [Abstract][Full Text] [Related]
8. Gene expression profiling in human precision cut liver slices in response to the FXR agonist obeticholic acid.
Ijssennagger N; Janssen AWF; Milona A; Ramos Pittol JM; Hollman DAA; Mokry M; Betzel B; Berends FJ; Janssen IM; van Mil SWC; Kersten S
J Hepatol; 2016 May; 64(5):1158-1166. PubMed ID: 26812075
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease.
Mudaliar S; Henry RR; Sanyal AJ; Morrow L; Marschall HU; Kipnes M; Adorini L; Sciacca CI; Clopton P; Castelloe E; Dillon P; Pruzanski M; Shapiro D
Gastroenterology; 2013 Sep; 145(3):574-82.e1. PubMed ID: 23727264
[TBL] [Abstract][Full Text] [Related]
10. Obeticholic acid protects against diabetic cardiomyopathy by activation of FXR/Nrf2 signaling in db/db mice.
Wu H; Liu G; He Y; Da J; Xie B
Eur J Pharmacol; 2019 Sep; 858():172393. PubMed ID: 31085240
[TBL] [Abstract][Full Text] [Related]
11. FXR agonists INT-787 and OCA increase RECK and inhibit liver steatosis and inflammation in diet-induced ob/ob mouse model of NASH.
Di Pasqua LG; Cagna M; Palladini G; Croce AC; Cadamuro M; Fabris L; Perlini S; Adorini L; Ferrigno A; Vairetti M
Liver Int; 2024 Jan; 44(1):214-227. PubMed ID: 37904642
[TBL] [Abstract][Full Text] [Related]
12. Obeticholic acid protects against hepatocyte death and liver fibrosis in a murine model of nonalcoholic steatohepatitis.
Goto T; Itoh M; Suganami T; Kanai S; Shirakawa I; Sakai T; Asakawa M; Yoneyama T; Kai T; Ogawa Y
Sci Rep; 2018 May; 8(1):8157. PubMed ID: 29802399
[TBL] [Abstract][Full Text] [Related]
13. Activation of FXR modulates SOCS3/Jak2/STAT3 signaling axis in a NASH-dependent hepatocellular carcinoma animal model.
Attia YM; Tawfiq RA; Gibriel AA; Ali AA; Kassem DH; Hammam OA; Elmazar MM
Biochem Pharmacol; 2021 Apr; 186():114497. PubMed ID: 33675775
[TBL] [Abstract][Full Text] [Related]
14. Isotschimgine alleviates nonalcoholic steatohepatitis and fibrosis via FXR agonism in mice.
Li J; Liu C; Zhou Z; Dou B; Huang J; Huang L; Zheng P; Fan S; Huang C
Phytother Res; 2021 Jun; 35(6):3351-3364. PubMed ID: 33784797
[TBL] [Abstract][Full Text] [Related]
15. CONTROL: A randomized phase 2 study of obeticholic acid and atorvastatin on lipoproteins in nonalcoholic steatohepatitis patients.
Pockros PJ; Fuchs M; Freilich B; Schiff E; Kohli A; Lawitz EJ; Hellstern PA; Owens-Grillo J; Van Biene C; Shringarpure R; MacConell L; Shapiro D; Cohen DE
Liver Int; 2019 Nov; 39(11):2082-2093. PubMed ID: 31402538
[TBL] [Abstract][Full Text] [Related]
16. Non-invasive evaluation of response to obeticholic acid in patients with NASH: Results from the REGENERATE study.
Rinella ME; Dufour JF; Anstee QM; Goodman Z; Younossi Z; Harrison SA; Loomba R; Sanyal AJ; Bonacci M; Trylesinski A; Natha M; Shringarpure R; Granston T; Venugopal A; Ratziu V
J Hepatol; 2022 Mar; 76(3):536-548. PubMed ID: 34793868
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of visceral adipose tissue-derived pathogenic signals by activation of adenosine A
Huang CC; Yeh HY; Lin R; Liao TL; Shen HC; Yang YY; Lin HC
Am J Physiol Gastrointest Liver Physiol; 2024 Apr; 326(4):G385-G397. PubMed ID: 38252682
[TBL] [Abstract][Full Text] [Related]
18. Cardiopulmonary protective effects of the selective FXR agonist obeticholic acid in the rat model of monocrotaline-induced pulmonary hypertension.
Vignozzi L; Morelli A; Cellai I; Filippi S; Comeglio P; Sarchielli E; Maneschi E; Vannelli GB; Adorini L; Maggi M
J Steroid Biochem Mol Biol; 2017 Jan; 165(Pt B):277-292. PubMed ID: 27425465
[TBL] [Abstract][Full Text] [Related]
19. REGENERATE: Design of a pivotal, randomised, phase 3 study evaluating the safety and efficacy of obeticholic acid in patients with fibrosis due to nonalcoholic steatohepatitis.
Ratziu V; Sanyal AJ; Loomba R; Rinella M; Harrison S; Anstee QM; Goodman Z; Bedossa P; MacConell L; Shringarpure R; Shah A; Younossi Z
Contemp Clin Trials; 2019 Sep; 84():105803. PubMed ID: 31260793
[TBL] [Abstract][Full Text] [Related]
20. Obeticholic acid prevents carbon tetrachloride-induced liver fibrosis through interaction between farnesoid X receptor and Smad3.
Fan YY; Ding W; Zhang C; Fu L; Xu DX; Chen X
Int Immunopharmacol; 2019 Dec; 77():105911. PubMed ID: 31671330
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
